GlassScriptPhysician profile
Oranu Ibekie
NPI 1134190713
$2,896.80
in general payments reported to CMS, 2019-2025
30 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $223 · 2021: $310 · 2022: $541 · 2023: $625 · 2024: $404 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $488.20 | 2020-2025 | Rexulti, Abilify Maintena |
| Indivior INC. | $386.16 | 2019-2025 | Sublocade |
| Novartis Pharmaceuticals Corporation | $302.80 | 2021-2023 | |
| Orexo US, INC. | $211.60 | 2019-2025 | Zubsolv |
| Lundbeck LLC | $168.43 | 2020-2025 | Rexulti |
| Alkermes, INC. | $127.26 | 2019-2024 | Vivitrol, Vivitrol |
| Astrazeneca Pharmaceuticals LP | $120.08 | 2021-2024 | Farxiga |
| Gilead Sciences, INC. | $110.93 | 2025 | Vemlidy |
| Bayer Healthcare Pharmaceuticals INC. | $88.90 | 2022 | |
| Neurocrine Biosciences, INC. | $87.33 | 2022-2025 | Ingrezza |
| Viiv Healthcare Company | $86.46 | 2024 | |
| Xeris Pharmaceuticals, INC. | $74.88 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $74.31 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $69.19 | 2023 | Xarelto |
| Pfizer INC. | $51.76 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $51.32 | 2022-2023 | Adlarity |
| Merck Sharp & Dohme LLC | $47.00 | 2023 | Verquvo |
| Hikma Pharmaceuticals USA | $41.62 | 2022 | |
| Sanofi Pasteur INC. | $38.44 | 2023 | |
| Avanir Pharmaceuticals, INC. | $36.36 | 2019 | |
| Braeburn INC. | $33.99 | 2024-2025 | Brixadi |
| Idorsia Pharmaceuticals US INC | $33.21 | 2023 | Quviviq |
| Novo Nordisk INC | $29.95 | 2025 | Wegovy |
| Exact Sciences Corporation | $23.95 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.68 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.96 | 2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $22.88 | 2021 | |
| Eisai INC. | $16.56 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.23 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $12.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oranu Ibekie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.